{"id":4716,"date":"2024-12-12T11:13:30","date_gmt":"2024-12-12T01:13:30","guid":{"rendered":"\/eu-uk\/?p=4716"},"modified":"2024-12-12T12:26:32","modified_gmt":"2024-12-12T02:26:32","slug":"orthocell-achieves-major-milestone-with-first-sales-of-remplir-in-singapore","status":"publish","type":"post","link":"\/eu-uk\/blog\/2024\/12\/12\/orthocell-achieves-major-milestone-with-first-sales-of-remplir-in-singapore\/","title":{"rendered":"Orthocell Achieves Major Milestone with First Sales of Remplir\u2122 in Singapore"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Orthocell has today announced the achievement of first sales of Remplir\u2122 in Singapore,\u00a0<\/span><span style=\"font-weight: 400;\">marking another significant milestone in its global commercialisation strategy.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This rapid commercialisation, from October 2024 regulatory approval to December 2024 first sales, demonstrates both the quality of the product, and the strength of Orthocell\u2019s partnership with Device Technologies Asia (DVT). Singapore represents a strategic gateway to the broader ASEAN market, in a global nerve repair market estimated to exceed US$3.5 billion.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">DVT Asia is well placed to gain sales traction in this strategic jurisdiction, having already established relationships with target customers including leading plastic reconstructive and orthopaedic surgeons at high quality surgical centres.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Orthocell Managing Director, Paul Anderson, said: <\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><i><span style=\"font-weight: 400;\">\u201cWe are delighted to report first sales to DVT Asia earlier than expected. Device Technologies is our chosen distribution partner in Australia, New Zealand and Singapore and have moved quickly to begin selling our leading nerve repair product Remplir in Singapore. We expect additional sales, revenue\u00a0growth and surgeon\u00a0adoption of Remplir to accelerate in the new year.\u201d\u00a0<\/span><\/i><\/p>\n<p><a href=\"https:\/\/bit.ly\/OCC-Singapore-Sales\"><b>Click here to read the ASX release.<\/b><b>\u00a0<\/b><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Orthocell has today announced the achievement of first sales of Remplir\u2122 in Singapore,\u00a0marking another significant milestone in its global commercialisation strategy.<\/p>\n","protected":false},"author":2,"featured_media":4719,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-4716","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news"],"aioseo_notices":[],"_links":{"self":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/comments?post=4716"}],"version-history":[{"count":1,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4716\/revisions"}],"predecessor-version":[{"id":4717,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4716\/revisions\/4717"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/media\/4719"}],"wp:attachment":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/media?parent=4716"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/categories?post=4716"},{"taxonomy":"post_tag","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/tags?post=4716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}